From May 28 to 29, the "Sencond-ever HKEx Biotech Summit " was grandly held in the Hong Kong City Hall of Finance. More than 1,000 experts from the biotech and financial industries around the world, including researchers in the life sciences, senior management of benchmarking enterprises, investment institutions, industrial funds and other financial institutions, as well as representatives of regulatory agencies, gathered here to share insights on the latest developments and trends in biotech industry and investment and financing. Carrie Lam Cheng Yuet-ngor, the Chief Executive of the Hong Kong Special Administrative Region; Luara M Cha, the HKEX Chairman; Charles Li, HKEX Chief Executive attended and delivered speeches. Jingtian & Gongcheng had the honor of being the only Chinese law firm among diamond sponsors of this event and participated in the whole process. Based on our rich first-hand experience, we shared with the participants the opportunities and challenges of listing and financing of biotech and medical enterprises in Hong Kong.
Jingtian & Gongcheng has been deeply engaged in China's legal market and domestic and overseas capital markets for many years in biotech and health care industries. At the same time, we also pay great attention to understanding and studying frontier issues and international innovation trends in related fields. Thanks to this, we have a more timely, clear and practical understanding and grasp of the dynamics of industry laws and the policy supervision of the industry.
We not only have rich service experience in traditional fields such as medical services and public health, medicine and medical devices, pension and health management industries, but also have participated in many emerging projects in depth in recent years, such as biopharmaceuticals and biotechnology, Internet applications in the field of health care, gene testing, medical big data, etc. We, representing many famous investment banks, industrial funds and other financial institutions, have participated in the investment, M & Aand capital market business of biotechnology and health care all the year round. We are also willing to grow up with corporate Clients and provide them with professional legal advice and intellectual property planning related to research and development, production, technical authorization, cooperative sales, registration, risk control and compliance management, thus contributing to the development of the company and protecting it. We serve many excellent enterprise customers in the industry, covering different stages of development such as start-up, unicorn and flagship enterprises. In recent years, we have successfully assisted more than a dozen major biotech and medical health enterprises in listing on Hong Kong, including: WuXi Biologics (02269.HK), Cornerstone Pharmaceutical (02616.HK), 3SBIO INC.(01530.HK), AK MEDICAL (01789.HK), RICI HEALTH (01526.HK), NC HEALTHCARE (01518.HK), HARMONICARE (01509.HK), CR MEDICAL(01515.HK), C-MER EYE (03309.HK), etc.
It is the consistent mission and vision of Jingtian & Gongcheng that we assist the connection between industry and capital through our legal services for promoting the development and standardization of the industry.
